ABL Diagnostics (XPAR:ABLD) EBIT : €0.16 Mil (TTM As of Jun. 2023)

View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics EBIT?

ABL Diagnostics's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was €-0.46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was €0.16 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ABL Diagnostics's annualized ROC % for the quarter that ended in Jun. 2023 was -10.36%. ABL Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -15.16%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ABL Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 0.31%.

ABL Diagnostics EBIT Historical Data

The historical data trend for ABL Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics EBIT Chart

ABL Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

0.06

-0.07

-0.09

-0.10

0.50

ABL Diagnostics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT	Get a 7-Day Free Trial															-0.05	-0.06	-0.12	0.62	-0.46

Competitive Comparison of ABL Diagnostics's EBIT

For the Health Information Services subindustry, ABL Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABL Diagnostics's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ABL Diagnostics's EV-to-EBIT falls into.

ABL Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.16 Mil.

ABL Diagnostics (XPAR:ABLD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ABL Diagnostics's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-0.926 * ( 1 - 0% )	/	( (8.845	+	9.04)	/ 2 )
=	-0.926	/	8.9425
=	-10.36 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	15.408	-	5.55	-	( 1.013	-	max(0, 5.55	-	11.986	+	1.013	))
=	8.845

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	16.372	-	5.787	-	( 1.545	-	max(0, 5.787	-	13.077	+	1.545	))
=	9.04

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

ABL Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.926	/	( ( (0.827 + max(5.247, 0))	+	(0.551 + max(5.589, 0)) )	/	2 )
=	-0.926	/	( ( 6.074	+	6.14 )	/	2 )
=	-0.926	/	6.107
=	-15.16 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.935	+	0.665	+	6.197)	-	(5.55	+	0	+	0)
=	5.247

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.296	+	0.758	+	6.322)	-	(5.787	+	0	+	0)
=	5.589

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ABL Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	0.158	/	50.456
	=	0.31 %

ABL Diagnostics EBIT Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Diagnostics (XPAR:ABLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

72c, rue de, WOIPPY, Thionville, FRA, 57140

Website

https://www.abldiagnostics.com

ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics (XPAR:ABLD) Headlines

No Headlines